Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. operates as a global diversified pharmaceutical company with business segments spanning gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and eye health. News related to Bausch Health may cover developments across any of these therapeutic areas, including product approvals, clinical trial results, regulatory actions, and commercial launches. The company's Salix business unit focuses on gastroenterology products, with particular emphasis on treatments for hepatic encephalopathy, irritable bowel syndrome, and other gastrointestinal conditions.
Corporate news may include updates on the company's debt management strategies, as Bausch Health has historically carried significant debt obligations stemming from acquisitions. Financial reporting typically addresses performance across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Bausch + Lomb eye health business represents a substantial portion of company operations and may generate independent news flow regarding vision care products, contact lenses, ophthalmic pharmaceuticals, and surgical equipment.
Dermatology news through the Ortho Dermatologics business may cover new acne treatments, psoriasis therapies, and other prescription dermatology products. Aesthetic medicine developments from Solta Medical often involve non-invasive cosmetic treatment technologies. Strategic acquisitions represent a key component of Bausch Health's growth strategy, with the company periodically acquiring businesses with complementary products in core therapeutic areas. Patent litigation and intellectual property matters frequently impact pharmaceutical companies, and Bausch Health may face generic competition for key products as patents expire.
Regulatory filings, including SEC reports, clinical trial registrations, and FDA submissions, provide transparency into company operations and pipeline developments. Investors monitor revenue trends across business segments, particularly the gastroenterology franchise which includes high-value products. Generic pharmaceutical competition, international market performance, and research and development progress all contribute to the ongoing narrative around this diversified pharmaceutical enterprise.
Bausch Health (NYSE:BHC) has expanded its Board of Directors from ten to twelve members with the appointment of two seasoned pharmaceutical industry executives, effective July 22, 2025. Michael Goettler, former CEO of Viatris, will serve on the Talent and Compensation Committee and Science and Technology Committee. Sandra Leung, former Executive VP and General Counsel of Bristol Myers Squibb, will join the Nominating and Corporate Governance Committee.
Board Chairman John A. Paulson expressed confidence that their extensive industry experience and leadership capabilities will provide strategic guidance for the company's continued evolution and strengthen its commitment to stakeholders.
Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as two federal programs - the Non-Insured Health Benefits (NIHB) for Indigenous populations and the Correctional Service of Canada (CSC).
CABTREO is a first-of-its-kind triple-combination topical prescription treatment for acne vulgaris, approved by Health Canada for patients 12 years and older. The treatment combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The once-daily gel is currently available through most private insurance plans, with plans to expand access through other public drug plans across Canada.
Bausch Health (NYSE:BHC) has appointed Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective July 14, 2025. Lee brings over two decades of experience in financial transformation, mergers and acquisitions, and operational execution.
Prior to joining Bausch Health, Lee served as Vice President and CFO of the Industrial and Energy Division and North America Division at BrandSafway, where he also held the position of Chief Accounting Officer. His previous experience includes leadership roles at Mohawk Industries as VP, Corporate Controller, and Chief Accounting Officer.
Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as federal programs NIHB and CSC. CABTREO is a first-of-its-kind triple-combination topical treatment for acne vulgaris in patients 12 years and older.
The prescription gel combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The treatment is administered once daily to affected skin areas and has already been available through most private drug insurance plans.
Bausch Health (NYSE:BHC) and its gastroenterology business, Salix Pharmaceuticals, have launched a new direct-to-consumer campaign called "I Wish I Knew" for their FDA-approved drug Xifaxan® (rifaximin). The campaign aims to educate about overt hepatic encephalopathy (OHE), a serious complication affecting cirrhosis patients.
The initiative features a 60-second spot highlighting a patient's journey with OHE and treatment with Xifaxan, alongside three new patient testimonials. The campaign emphasizes that up to 80% of cirrhosis patients may develop some form of hepatic encephalopathy, which can cause alterations in consciousness, cognition, and behavior.
The company is collaborating with patient advocacy organizations including Global Liver Institute and American Liver Foundation to raise awareness about chronic liver disease progression and OHE management.
Bausch Health (NYSE:BHC) has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. EDT to discuss the results and provide a business update.
The presentation materials will be available on the company's Investor Relations website before the call, and a replay will be accessible afterward at ir.bauschhealth.com/events-and-presentations.
Bausch Health Companies (NYSE/TSX: BHC) held its 2025 Annual Meeting of Shareholders on May 13, 2025, where shareholders elected all 10 nominated directors to the board. The meeting saw significant participation with vote counts ranging from approximately 199-208 million votes in favor for different directors. Notable directors elected include Thomas J. Appio, Brett M. Icahn, and John A. Paulson.
Additionally, shareholders approved three key items: a non-binding advisory vote on executive compensation, the 2025 Employee Stock Purchase Plan (ESPP), and the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm through the 2026 annual meeting.
Bausch Health Companies announced new data showing that patients hospitalized for overt hepatic encephalopathy (OHE) had a reduced risk of 30-day rehospitalization when treated with Xifaxan® (rifaximin) after discharge, regardless of prior treatment. The claims-based analysis of 7,880 OHE patients revealed that those receiving only lactulose upon discharge had a higher risk of 30-day OHE rehospitalization compared to Xifaxan recipients (adjusted OR: 1.63-2.73, p<0.05).
Prior to hospitalization, 27.1% of patients were treated with Xifaxan, 24.1% with lactulose, and 48.8% received no treatment. The findings support AASLD treatment guidelines recommending Xifaxan as an add-on to lactulose after breakthrough OHE episodes to prevent recurrence. Up to 80% of cirrhosis patients eventually develop some form of HE.
Bausch Health reported strong Q1 2025 financial results with consolidated revenues of $2.26 billion, marking a 5% increase year-over-year. The company achieved its eighth consecutive quarter of growth, with a 6% revenue increase and 14% Adjusted EBITDA growth for Bausch Health excluding Bausch + Lomb.
Key highlights include:
- Salix segment grew 9% to $542 million
- Solta Medical segment surged 28% to $113 million
- Bausch + Lomb segment increased 3% to $1.14 billion
Despite posting a GAAP net loss of $58 million, the company successfully completed a $7.9B refinancing in April to extend maturities. Bausch Health maintained its full-year 2025 Revenue and Adjusted EBITDA guidance while updating its Adjusted Cash Flow from Operations guidance to reflect higher interest expenses.
Bausch Health and its aesthetic business Solta Medical have received Health Canada clearance for their Thermage FLX system, an advanced non-invasive radiofrequency skin tightening technology.
The fourth-generation Thermage FLX system offers several key improvements:
- 25% faster treatments with a larger 4.0 cm² treatment tip
- Enhanced patient comfort through integrated vibration and cooling
- Smart AccuREP technology that adjusts RF energy based on skin impedance
- Ergonomic handpiece design for improved provider workflow
- Versatile applications for face, eyes, and body treatments
This approval marks a significant milestone for Bausch Health's aesthetic business growth in Canada, bringing the same advanced technology already used in leading aesthetic clinics worldwide to Canadian providers and patients. The system builds on Thermage's 20-year legacy of trusted non-invasive skin tightening solutions.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
